TrialAnnals of the rheumatic diseases2012

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.

Ronald F van Vollenhoven et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.